180
Views
3
CrossRef citations to date
0
Altmetric
Papillophlebitis and OC

Papillophlebitis associated with the use of oral contraceptive: a case report

, , , &
Pages 601-603 | Received 16 Dec 2014, Accepted 26 May 2015, Published online: 17 Aug 2015
 

Abstract

We present a 20-year-old female patient with papillophlebitis in the right eye. Minimal expansion of the blind spot and nasal peripheral defects in the right eye visual field were detected. The patient was using ethinyl estradiol-cyproterone acetate for ovarian cyst and menstrual irregularity. An improvement in the patient's visual field began within a week after cessation of ethinyl estradiol-cyproterone acetate. Ophthalmoscopic findings resolved completely in the sixth week. This situation suggests that female sex hormones or thromboembolic process caused by them may be responsible for the pathogenesis of papillophlebitis. But the exact mechanism in the pathogenesis of papillophlebitis is still controversial.

Chinese abstract

我们报告一位患右眼视乳头静脉炎的20岁女性患者。其右眼视野中盲点和鼻周边缺损的最小扩展被检测到。病人曾因卵巢囊肿和月经不调使用炔雌醇环丙孕酮。停用炔雌醇环丙孕酮一周后,患者视野开始改善。停药后第六周,眼底检查完全恢复。这种情况表明,雌性激素或血栓栓塞过程可能是视乳头静脉炎的发病机制。但是视乳头静脉炎的具体机制仍有争议。

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Notes

* This study was presented at 48th National Congress of the Turkish Ophthalmology Society Antalya/Turkey on 5–9 November 2014.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.